Cargando…

Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies

Antibody gene transfer presents an appealing alternative to conventional antibody protein therapy. This pre-clinical study evaluates the impact of various parameters on the pharmacokinetics and efficacy of in vivo expressed DNA-based anti-HER2 monoclonal antibodies (mAbs), newly engineered and deliv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hollevoet, Kevin, De Smidt, Elien, Geukens, Nick, Declerck, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862603/ https://www.ncbi.nlm.nih.gov/pubmed/29568382 http://dx.doi.org/10.18632/oncotarget.24426

Ejemplares similares

Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer
por: Jacobs, Liesl, et al.
Publicado: (2020)

Long-term in vivo expression of trastuzumab following intramuscular electrotransfer of the encoding DNA in mice
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Exploring the Fate of Antibody-Encoding pDNA after Intramuscular Electroporation in Mice
por: Cuypers, Marie-Lynn, et al.
Publicado: (2023)

Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
por: Hollevoet, Kevin, et al.
Publicado: (2022)

State of play and clinical prospects of antibody gene transfer
por: Hollevoet, Kevin, et al.
Publicado: (2017)

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
por: Gils, Ann, et al.
Publicado: (2014)

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model
por: Imbrechts, Maya, et al.
Publicado: (2022)

A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo
por: Shu, Mengjun, et al.
Publicado: (2020)

A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo
por: Mohammadi, Mehdi, et al.
Publicado: (2021)

Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2
por: Kim, H, et al.
Publicado: (2016)

Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes
por: Kolyvas, Emily, et al.
Publicado: (2016)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors
por: Gan, Hui K., et al.
Publicado: (2021)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
por: Chen, I-Chun, et al.
Publicado: (2021)

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2
por: Kunisue, H, et al.
Publicado: (2000)

Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer
por: Cordero, Alex, et al.
Publicado: (2021)

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
por: Mason-Osann, Emily, et al.
Publicado: (2015)

Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo
por: Foy, Kevin C., et al.
Publicado: (2012)

In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines
por: Dokduang, Hasaya, et al.
Publicado: (2020)

Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
por: Su, Chia-Yu, et al.
Publicado: (2018)

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
por: Ceran, Ceyhan, et al.
Publicado: (2012)

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
por: Nordstrom, Jeffrey L, et al.
Publicado: (2011)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Prolonged viral suppression with anti-HIV-1 antibody therapy
por: Gaebler, Christian, et al.
Publicado: (2022)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
por: Haense, N., et al.
Publicado: (2016)

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients
por: Schelpe, An-Sofie, et al.
Publicado: (2019)

Conformational characterization of a novel anti-HER2 candidate antibody
por: Moro Pérez, Leina, et al.
Publicado: (2019)

An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
por: Weisser, Nina E., et al.
Publicado: (2023)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells
por: Li, Ruilin, et al.
Publicado: (2016)

Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model
por: Wang, Li, et al.
Publicado: (2011)

Persistent Expression of Biologically Active Anti-HER2 Antibody by AAVrh.10-mediated Gene Transfer
por: Wang, Guoqing, et al.
Publicado: (2010)

AllergoOncology: Expression platform development and functional profiling of an anti‐HER2 IgE antibody
por: Ilieva, Kristina M., et al.
Publicado: (2019)

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
por: Cheng, Jackie, et al.
Publicado: (2020)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
por: Rabia, Emilia, et al.
Publicado: (2021)

The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice
por: Li, Panyuan, et al.
Publicado: (2020)

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting
por: Meyer, Saskia, et al.
Publicado: (2015)

Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
por: Oganesyan, Vaheh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3mvji073prpp3fqap7g18haqmp